- Insulin
- Biguanides
- Sulfonyl Ureas
- Thiazolidinediones
- Di Peptidyl Peptidase (DPP)-IV Inhibitors
- ?-glucosidase Inhibitos
- GLP-1 Agonists
- Others
Antidiabetic Biosimilars Market size was valued at USD x million in 2022 and is poised to grow at a CAGR of x% from 2023 - 2029. Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules. Antidiabetics help diabetic people control their blood glucose levels. Biguanides, thiazolidinediones, DPP-IV inhibitors, -glucosidase inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists like exenatide are examples of antidiabetics. A biosimilar product is a biological product that has been approved by the FDA because it is very similar to an FDA-approved biological product called a reference product. To demonstrate that the biosimilar manufactured gives the same therapeutic benefit to patients as the reference medication, biosimilar manufacturers must generate data from lab testing and clinical testing.
Key Developments: In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Drivers: Increase in the prevalence of diabetic patients Patent expiries block buster drugs and promising product pipeline Government initiations to control the diabetes Restraints: High cost of R&D activities Stringent regulatory policies Complexity in development of biosimilars
The anti-diabetic biosimilars market, size was valued at USD x million in 2022
The anti diabetic biosimilars market, key players are: Biocon (India) Merck Sharp & Dohme Corporation (U.S.) Boehringer Ingelheim GmbH (Germany) Eli Lilly & Co. (U.S.) Sanofi-aventis U.S. LLC (U.S.) Samsung Bioepis (Samsung BioLogics) (South Korea) Mylan N.V. (U.S.) Wockhardt (India)
The anti diabetic biosimilars market, has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Anti-diabetic Biosimilars Market Introduction |
2.1. Global Anti-diabetic Biosimilars Market Taxonomy |
2.2. Global Anti-diabetic Biosimilars Market Definitions |
2.2.1. Drug Class |
2.2.2. Disease Type |
2.2.3. Distribution Channel |
3. Global Anti-diabetic Biosimilars Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Anti-diabetic Biosimilars Market Dynamic Factors - Impact Analysis |
3.6. Global Anti-diabetic Biosimilars Market Competition Landscape |
3.7. Epidemiology |
4. Global Anti-diabetic Biosimilars Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Anti-diabetic Biosimilars Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1. Insulin |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Biguanides |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Sulfonyl Ureas |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Thiazolidinediones |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. α-glucosidase Inhibitors |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. GLP-1 Agonists |
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Others |
5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
6. Global Anti-diabetic Biosimilars Market Forecast, By Disease Type, 2018 - 2022 and Forecast, 2023 - 2029 |
6.1. Type-I Diabetes |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Type-II Diabetes |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Anti-diabetic Biosimilars Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Anti-diabetic Biosimilars Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2023 - 2029 |
9. North America Anti-diabetic Biosimilars Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 |
9.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 |
9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 |
9.4. Country Analysis 2016 and Forecast 2023 - 2029 |
9.5. North America Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2023 - 2029 |
9.6. North America Anti-diabetic Biosimilars Market Dynamics – Trends |
10. Europe Anti-diabetic Biosimilars Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 |
10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 |
10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 |
10.5. Europe Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2023 - 2029 |
10.6. Europe Anti-diabetic Biosimilars Market Dynamics – Trends |
11. Asia-Pacific Anti-diabetic Biosimilars Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 |
11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 |
11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 |
11.5. Asia-Pacific Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2023 - 2029 |
11.6. Asia-Pacific Anti-diabetic Biosimilars Market Dynamics – Trends |
12. Latin America Anti-diabetic Biosimilars Market Analysis, 2012 - 2012 - 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 |
12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 |
12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 |
12.5. Latin America Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2023 - 2029 |
12.6. Latin America Anti-diabetic Biosimilars Market Dynamics – Trends |
13. Middle East and Africa Anti-diabetic Biosimilars Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 |
13.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 |
13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 |
13.5. MEA Anti-diabetic Biosimilars Market Opportunity Analysis Index, By Drug Class, By Disease Type, By Distribution Channel, and Region, 2023 - 2029 |
13.6. MEA Anti-diabetic Biosimilars Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. Biocon (India) |
14.2.2. Merck Sharp & Dohme Corporation (U.S.) |
14.2.3. Boehringer Ingelheim GmbH (Germany) |
14.2.4. Eli Lilly & Co. (U.S.) |
14.2.5. Sanofi-aventis U.S. LLC (U.S.) |
14.2.6. Samsung Bioepis (Samsung BioLogics) (South Korea) |
14.2.7. Mylan N.V. (U.S.) |
14.2.8. Wockhardt (India) |
15. Research Methodology |
16. Key Assumptions and Acronyms |